Researchers from the OSU College of Pharmacy, led by Oleh Taratula, Olena Taratula, and Chao Wang, have made a groundbreaking discovery published in Advanced Functional Materials.
Enhancing Chemodynamic Therapy
This innovative work bolsters the promising field of chemodynamic therapy (CDT), a novel approach to cancer treatment that leverages the unique chemical environment within tumors. Cancer cells are typically more acidic and contain elevated levels of hydrogen peroxide compared to normal tissues.
Traditional CDT utilizes these tumor characteristics to generate hydroxyl radicals--highly reactive molecules that damage cellular components through oxidation. Recent advancements in CDT have also successfully produced singlet oxygen, another reactive species characterized by its distinct electron spin state.
Addressing Limitations of Current CDT Agents
Oleh Taratula noted, "Current CDT agents have limitations; they can generate either hydroxyl radicals or singlet oxygen, but not both. Furthermore, they often lack the catalytic activity necessary for sustained production of reactive oxygen species, leading to only partial tumor regression in preclinical studies."
To overcome these challenges, the research team developed an innovative CDT nanoagent based on an iron-based metal-organic framework (MOF). This novel structure is capable of generating both hydroxyl radicals and singlet oxygen, significantly enhancing its effectiveness against cancer. The MOF exhibited substantial toxicity against various cancer cell lines while sparing healthy cells.
Complete Tumor Elimination in Animal Models
In experiments involving mice with human breast cancer cells, the nanoagent was administered systemically, where it effectively concentrated in tumors and generated reactive oxygen species, leading to complete cancer eradication without adverse effects. "We observed total tumor regression and long-term prevention of recurrence, all without systemic toxicity," stated Olena Taratula. The tumors completely vanished and did not reappear, with no harmful side effects observed in the animals.
Future Directions for Cancer Treatment
Before transitioning to human trials, the research team plans to explore the treatment's efficacy on other cancer types, including aggressive pancreatic cancer, to assess its broader applicability across various malignancies.
Additional contributors to this research include Kongbrailatpam Shitaljit Sharma, Yoon Tae Goo, Vladislav Grigoriev, Constanze Raitmayr, Ana Paula Mesquita Souza, and Manali Parag Phawde. The project received funding from the National Cancer Institute and the Eunice Kennedy Shriver National Institute of Child Health and Human Development.